Background
- Metaplastic Breast Cancer (MBC) is rare and aggressive form of BC with majority having triple-negative receptor status.
- There are no standard therapeutic approaches for MBC and majority are treated similar to invasive ductal triple negative breast cancer (ID-TNBC) but with worse outcomes in comparison to other BC subtypes.
- There is an urgent need for new drug targets and therapies for MBC. Here, we characterize the molecular and immune signature of metaplastic TNBC (M-TNBC).